TSX:RVX - Post Discussion
Post by
G1945V on Mar 20, 2023 8:27am
$%6M Debenture Extended
"The steadfast commitment of our partners allows us to focus on our mutual goal of advancing apabetalone's clinical development, for the benefit of chronic disease patients. Over the past several months we have been working diligently with Hepalink in order to prepare for their involvement in our upcoming BETonMACE2 trial which has FDA Breakthrough Therapy Designation." G1945V
Be the first to comment on this post